Keratin 34betaE12/keratin7 expression is a prognostic factor of cancer-specific and overall survival in patients with early stage non-small cell lung cancer

Background. Carcinomas and their metastases often retain the keratin patterns of their epithelial origin, and are therefore useful as lineage-specific markers in diagnostic pathology. Recently, it has become clear that intermediate filaments composed by keratins play a role in modulation of cell proliferation, migration, and possibly cancer invasion, factors impacting prognosis in early stage non-small cell lung cancer (NSCLC). Material and methods. Tumor tissue from a retrospective Danish cohort of 177 patients with completely resected NSCLC, stage I-IIIA tumors, were analyzed for keratin 7 (K7) and keratin 34βE12 expression by immunohistochemistry and validated in a comparable independent Norwegian cohort of 276 stage I-IIIA NSCLC patients. Results. Based on keratin 34βE12/K7 expression, three subgroups with significantly different median cancer-specific survival rates were identified (34βE12+/K7+, 168 months vs. 34βE12+/K7+, 73 months vs. 34βE12-/K7+, 30 months; p = 0.0004). In multivariate analysis, stage II-IIIA (HR 2.9), 34βE12+/K7+ (HR 1.90) and 34βE12-/K7+ (HR 3.7), were prognostic factors of poor cancer-specific survival (CSS) (p < 0.001). Validation in the Norwegian cohort confirmed that stage II-IIIA (HR 2.3), 34βE12+/K7+ (HR 1.6), and 34βE12-/K7+ (HR 2.0) were prognostic factors of poor CSS (p < 0.05). Multivariate Cox proportional-hazard analysis demonstrated that 34βE12+/K7 + and 34βE12+/K7 + status was significantly associated with poor overall survival (p < 0.05). Conclusion. Keratin 34βE12/K7 expression is a prognostic parameter in resected early stage NSCLC that allows identification of high-risk NSCLC patients with poor cancer-specific and overall survival.

[1]  H. Ditzel,et al.  Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[2]  D. Carbone,et al.  Early Stage Lung Cancer: Progress in the Last 40 Years , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  H. Ditzel,et al.  Tissue microarrays in non-small-cell lung cancer: reliability of immunohistochemically-determined biomarkers. , 2014, Clinical lung cancer.

[4]  J. Käs,et al.  Keratins significantly contribute to cell stiffness and impact invasive behavior , 2013, Proceedings of the National Academy of Sciences.

[5]  J. Douillard,et al.  Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial. , 2011, Lung cancer.

[6]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  V. Karantza,et al.  Keratins in health and cancer: more than mere epithelial cell markers , 2011, Oncogene.

[8]  T. Dønnem,et al.  Combination of low vascular endothelial growth factor A (VEGF‐A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer , 2010, Cancer.

[9]  N. Sneige,et al.  Expression of high-molecular-weight cytokeratin (34βE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast , 2010, Journal of Clinical Pathology.

[10]  S. Burdett,et al.  Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. , 2010 .

[11]  R. Moll,et al.  The human keratins: biology and pathology , 2008, Histochemistry and Cell Biology.

[12]  T. Dønnem,et al.  Inverse Prognostic Impact of Angiogenic Marker Expression in Tumor Cells versus Stromal Cells in Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.

[13]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  V. Capelozzi,et al.  Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. , 2006, Human pathology.

[15]  for the Statistics Subcommittee of the NCI—EORTC Worki Diagnostics.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[16]  E. Brambilla,et al.  34βE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma , 2003 .

[17]  M. Bongiovanni,et al.  34βE 12 Cytokeratin Immunodetection in the Differential Diagnosis of Small Cell Tumors of Lung , 2000, International journal of surgical pathology.

[18]  A. Ambergen,et al.  Number and proliferation of basal and parabasal cells in normal human airway epithelium. , 1998, American journal of respiratory and critical care medicine.

[19]  Mary J. C. Hendrix,et al.  Role of intermediate filaments in migration, invasion and metastasis , 1996, Cancer and Metastasis Reviews.

[20]  E. Lane,et al.  Expression of intermediate filament proteins in fetal and adult human lung tissues. , 1989, Differentiation; research in biological diversity.

[21]  Benjamin Geiger,et al.  The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells , 1982, Cell.

[22]  B. Corfe,et al.  Alteration in composition of keratin intermediate filaments in a model of breast cancer progression and the potential to reverse hallmarks of metastasis. , 2012, Cancer biomarkers : section A of Disease markers.

[23]  Teruhiko Yoshida,et al.  Expression of cytokeratin 7 predicts survival in stage I/IIA/IIB squamous cell carcinoma of the esophagus. , 2008, Oncology reports.

[24]  R. Nagle,et al.  Cell Adhesion and Cytoskeletal Molecules in Metastasis , 2006 .

[25]  E. Brambilla,et al.  34BetaE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma. , 2003, Histopathology.

[26]  David E. Misek,et al.  Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. , 2002, Neoplasia.